Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eczema drug shows promise in early trial

NCT ID NCT06723405

Symptom relief Sponsor: Evommune, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an experimental drug, EVO301, in 71 adults with moderate-to-severe atopic dermatitis (eczema). The goal was to see if it safely reduces skin redness, thickness, and itch. Participants received either EVO301 or a placebo, and doctors measured changes in skin severity over time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

71 people

The number who actually took part.

Started

Feb 2025

Finished

Nov 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Males or non-pregnant, non-lactating females, age 18 years or older 2. Chronic atopic dermatitis for at least 6 months 3. BSA of AD involvement of at least 10% 4. EASI score of at least 16. Exclusion Criteria: 1. Significant AD flare with 4 weeks 2. Use of biologic therapy within 12 weeks 3. Regular use of tanning booth within 4 weeks 4. Skin condition that could interfere with study assessments

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atopic dermatitis (AD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atopic eczema Eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atopic dermatitis (AD) Eczema Eczema atopic dermatitis

Contacts and locations

Locations

  • Clinical Trials New Zealand Ltd

    Hamilton, 3204, New Zealand

  • Cornerstone Dermatology

    Coorparoo, QLD 4151, Australia

  • Momentum Clinical Research Darlinghurst

    Darlinghurst, NSW 2010, Australia

  • Momentum Clinical Research Dunedin

    Dunedin, 9016, New Zealand

  • Momentum Clinical Research Kapiti

    Paraparaumu, 5032, New Zealand

  • Momentum Clinical Research Lower Hutt

    Hutt Central, 5010, New Zealand

  • Momentum Clinical Research Pukekohe

    Pukekohe, 2120, New Zealand

  • Optimal Clinical Trials

    Auckland, 1010, New Zealand

  • Optimal Clinical Trials North

    Auckland, 0632, New Zealand

  • Pacific Clinical Research Network (PCRN) Auckland

    Auckland, 0622, New Zealand

  • Pacific Clinical Research Network (PCRN) Christchurch

    Christchurch, 8013, New Zealand

  • Pacific Clinical Research Network (PCRN) Tasman

    Nelson, 7011, New Zealand

More trials for these conditions

Other studies related to the condition(s) this trial covers.